

Supporting Information

Cu(OAc)₂ · H₂O/NH₂NH₂ · H₂O: An Efficient Catalyst System *in situ* Generating Cu₂O Nanoparticles and HOAc for Huisgen-Click Reaction

Yuqin Jiang*, Duanyang Kong, Jinglin Zhao, Qinghua Qi, Wei Li, Guiqing Xu*
School of Chemistry and Chemical Engineering, Henan Normal University, Xixiang
453007, Henan, P. R. China
E-mail: jiangyuqin@htu.cn.

Table of contents

I. General Informationn	S2
II. Catalyst characterization	S2-4
III. General procedure for the synthesis of triazoles	S4
IV. ¹ H and ¹³ C NMR Data of the Products	S5-10
V. ¹ H and ¹³ C NMR Spectra of the Products.....	S11-30


I. General Information:

All reagents were purchased from commercial sources and used without further treatment, unless otherwise indicated. The catalysts were characterized using X-ray powder diffraction (XRD) (Bruker D8 Advance), scanning electron microscope (SEM) (JSM-6390LV) and transmission electron microscope (TEM) (JEM-2100). The products were characterized using ^1H NMR and ^{13}C NMR (Bruker Avance/400) which used CDCl_3 or DMSO-d_6 as the solvent and TMS as internal standard. Data is represented as follows: chemical shift, integration, multiplicity (s = singlet, d = doublet, dd = double of doublets, t = triplet, q = quartet, m = multiplet, br = broad) and coupling constants (J) in Hertz (Hz).


II. Catalyst characterization




(a) The suspension of catalyst system



(b) XRD pattern of the catalyst



(c) SEM image of the catalyst




(d) TEM image of the catalyst

XRD peaks at 36.56 °, 42.55 °, 62.77 ° and 73.93 ° respectively belong to Cu₂O (111), Cu₂O (200), Cu₂O (220) and Cu₂O (311) which clearly demonstrate that the catalysts are Cu₂O. The catalysts are proved to be hollow spherical Cu₂O-NPs of sizes 400-500 nm by SEM and TEM.


III. General procedure for the synthesis of triazoles

Alkyne (1mmol), azide (1mmol), Cu(OAc)₂ · H₂O (0.02 mmol) were dissolved (suspended) in deionized water (1mL) and then NH₂NH₂ · H₂O (0.01 mmol) was added to the suspension. The product was precipitated within a short time (see **Table 1** for exact reaction time). After the completion of the reaction, the resulting solution was extracted with EtOAc. The organic phase was dried with anhydrous Na₂SO₄, and the solvent was removed in vacuo to give the corresponding triazoles, which were purified by column chromatography (petroleum ether/EtOAc).


IV. ^1H and ^{13}C NMR Data of the Products




ethyl 2-(4-(phenoxy)methyl)-1H-1,2,3-triazol-1-yl)acetate (Table 1, entry 1): ^1H NMR (CDCl_3 , 400 MHz) δ : 7.74 (s, 1H), 7.30-6.94 (m, 5H), 5.21 (s, 2H), 5.13 (s, 2H), 4.23 (q, $J = 7.2$ Hz, 2H), 1.27 (t, $J = 7.2$ Hz, 3H). ^{13}C NMR (CDCl_3 , 100 MHz) δ : 166.3, 158.2, 144.6, 129.6, 124.3, 121.3, 114.8, 62.4, 61.8, 50.9, 14.0.




1-(4-methoxyphenyl)-4-(phenoxy)methyl)-1H-1,2,3-triazole (Table 1, entry 2): ^1H NMR (CDCl_3 , 400 MHz) δ : 7.97 (s, 1H), 7.64-7.60 (m, 2H), 7.33-7.29 (m, 2H), 7.03-6.99 (m, 5H), 5.28 (s, 2H), 3.85 (s, 3H). ^{13}C NMR (CDCl_3 , 100 MHz) δ : 159.9, 158.2, 144.8, 130.4, 129.6, 122.3, 121.3, 121.1, 114.8 (2), 62.0, 55.6.




1-benzyl-4-(phenoxy)methyl)-1H-1,2,3-triazole (Table 1, entry 3): ^1H NMR (CDCl_3 , 400 MHz) δ : 7.53 (s, 1H), 7.38-7.26 (m, 7H), 6.97 (d, $J = 8.0$ Hz, 3H), 5.53 (s, 2H), 5.19 (s, 2H). ^{13}C NMR (CDCl_3 , 100 MHz) δ : 158.2, 144.7, 134.5, 129.5, 129.2, 128.8, 128.1, 122.6, 121.3, 114.8, 62.1, 54.3.




4-(phenoxy)methyl)-1-phenyl-1H-1,2,3-triazole (Table 1, entry 4): ^1H NMR (CDCl_3 , 400 MHz) δ : 8.06 (s, 1H), 7.74 (d, $J = 7.6$ Hz, 2H), 7.55-7.43 (m, 3H), 7.32 (t, $J = 8.0$ Hz, 2H), 7.04-6.98 (m, 3H), 5.31 (s, 2H). ^{13}C NMR (CDCl_3 , 100 MHz) δ : 158.2, 145.1, 137.0, 129.8, 129.6, 128.9, 121.4, 120.9, 120.6, 114.8, 62.0.




ethyl 2-(4-(p-tolyl)-1H-1,2,3-triazol-1-yl)acetate (Table 1, entry 5): ^1H NMR (CDCl_3 , 400 MHz) δ : 7.87 (s, 1H), 7.73 (d, J = 8.0 Hz, 2H), 7.24 (t, J = 8.0 Hz, 2H), 5.19 (s, 2H), 4.28 (q, J = 8.0 Hz, 2H), 2.38 (s, 3H), 1.30 (t, J = 7.2 Hz, 3H). ^{13}C NMR (CDCl_3 , 100 MHz) δ : 166.4, 148.3, 138.2, 129.5, 127.5, 125.7, 120.7, 62.5, 51.0, 21.3, 14.1.




1-benzyl-4-(p-tolyl)-1H-1,2,3-triazole (Table 1, entry 6): ^1H NMR (CDCl_3 , 400 MHz) δ : 7.69 (d, J = 7.6 Hz, 2H), 7.63 (s, 1H), 7.38-7.29 (m, 5H), 7.20 (d, J = 8.0 Hz, 2H), 5.55 (s, 2H), 2.36 (s, 3H). ^{13}C NMR (CDCl_3 , 100 MHz) δ : 148.3, 138.0, 134.8, 129.5, 129.2, 128.8, 128.1, 127.7, 125.6, 119.2, 54.2, 21.3.




1-phenyl-4-(p-tolyl)-1H-1,2,3-triazole (Table 1, entry 7): ^1H NMR (CDCl_3 , 400 MHz) δ : 8.16 (s, 1H), 7.80 (dd, J = 6.0 Hz, 7.6 Hz, 4H), 7.57-7.26 (m, 5H), 2.40 (s, 3H). ^{13}C NMR (CDCl_3 , 100 MHz) δ : 148.5, 138.3, 137.1, 129.8, 129.6, 128.7, 127.4, 125.8, 120.5, 117.3, 21.3.




1-(3-chlorobenzyl)-4-(p-tolyl)-1H-1,2,3-triazole (Table 1, entry 8): ^1H NMR (CDCl_3 , 400 MHz) δ : 7.70 (d, J = 8.0 Hz, 2H), 7.66 (s, 1H), 7.35-7.17 (m, 6H), 5.54 (s, 2H), 2.37 (s, 3H). ^{13}C NMR (CDCl_3 , 100 MHz) δ : 148.5, 138.2, 136.7, 135.1, 130.5, 129.5, 129.0, 128.1, 127.5, 126.1, 125.7, 119.2, 53.5, 21.3.




1-(4-nitrobenzyl)-4-(p-tolyl)-1H-1,2,3-triazole (Table 1, entry 9): ^1H NMR (CDCl_3 , 400 MHz) δ : 8.17 (d, J = 8.0 Hz, 2H), 7.75 (s, 1H), 7.68 (d, J = 8.0 Hz, 2H), 7.40 (d, J = 8.0 Hz, 2H), 7.20 (d, J = 8.0 Hz, 2H), 5.65 (s, 2H), 2.35 (s, 3H). ^{13}C NMR (CDCl_3 , 100 MHz) δ : 148.7, 148.0, 141.9, 138.4, 129.6, 128.6, 127.3, 125.6, 124.3, 119.6, 53.1, 21.3.



1-(2-methyl-5-nitrophenyl)-4-(p-tolyl)-1H-1,2,3-triazole (Table 1, entry 10): ^1H NMR (CDCl_3 , 400 MHz) δ : 8.29-8.27 (m, 2H), 8.02 (s, 1H), 7.80 (d, J = 8.0 Hz, 2H), 7.60 (d, J = 9.2 Hz, 1H), 7.28 (d, J = 8.0 Hz, 2H), 2.44 (s, 3H), 2.41 (s, 3H). ^{13}C NMR (CDCl_3 , 100 MHz) δ : 148.2, 146.4, 141.6, 138.6, 136.8, 132.6, 129.6, 126.9, 125.7, 124.2, 121.1, 120.7, 21.3, 18.6.




1-benzyl-4-cyclopropyl-1H-1,2,3-triazole (Table 1, entry 11): ^1H NMR (CDCl_3 , 400 MHz) δ : 7.37-7.22 (m, 5H), 7.14 (s, 1H), 5.44 (s, 2H), 1.93-1.86 (m, 1H), 0.92-0.88 (m, 2H), 0.82-0.78 (m, 2H). ^{13}C NMR (CDCl_3 , 100 MHz) δ : 150.7, 134.9, 129.0, 128.6, 128.0, 119.6, 54.0, 7.7, 6.7.




1-benzyl-4-((4-chlorophenoxy)methyl)-1H-1,2,3-triazole (Table 1, entry 12): ^1H NMR (CDCl_3 , 400 MHz) δ : 7.53 (s, 1H), 7.36-7.24 (m, 5H), 7.20 (d, J = 8.0 Hz, 2H),


6.88 (d, $J = 8.0$ Hz, 2H), 5.50 (s, 2H), 5.12 (s, 2H). ^{13}C NMR (CDCl_3 , 100 MHz) δ : 156.8, 144.1, 134.5, 129.4, 129.2, 128.9, 128.1, 126.1, 122.8, 116.2, 62.3, 54.2.




4-((4-chlorophenoxy)methyl)-1-phenyl-1H-1,2,3-triazole (Table 1, entry 13): ^1H NMR (CDCl_3 , 400 MHz) δ : 8.05 (s, 1H), 7.72 (dd, $J = 8.0$ Hz, 2.0 Hz, 2H), 7.54-7.43 (m, 3H), 7.25 (dd, $J = 6.8$ Hz, 2.4 Hz, 2H), 6.95 (dd, $J = 6.8$ Hz, 2.4 Hz, 2H), 5.26 (s, 2H). ^{13}C NMR (CDCl_3 , 100 MHz) δ : 156.8, 144.6, 136.9, 129.8, 129.5, 129.0, 126.3, 121.0, 120.6, 116.1, 62.2.




4-((4-chlorophenoxy)methyl)-1-(4-nitrobenzyl)-1H-1,2,3-triazole (Table 1, entry 14): ^1H NMR ($\text{DMSO}-d_6$, 400 MHz) δ : 8.37 (s, 1H), 8.25 (d, $J = 8.4$ Hz, 2H), 7.53 (d, $J = 8.4$ Hz, 2H), 7.34 (d, $J = 8.8$ Hz, 2H), 7.07 (d, $J = 8.8$ Hz, 2H), 5.81 (s, 2H), 5.16 (s, 2H). ^{13}C NMR ($\text{DMSO}-d_6$, 100 MHz) δ : 157.2, 147.6, 143.8, 143.3, 129.7, 129.4, 125.6, 125.1, 124.3, 116.9, 61.8, 52.4.




1-benzyl-4-(4-ethylphenyl)-1H-1,2,3-triazole (Table 1, entry 15): ^1H NMR (CDCl_3 , 400 MHz) δ : 7.71 (d, $J = 8.0$ Hz, 2H), 7.63 (s, 1H), 7.37-7.27 (m, 5H), 7.22 (d, $J = 8.0$ Hz, 2H), 5.53 (s, 2H), 2.65 (q, $J = 7.6$ Hz, 2H), 1.23 (t, $J = 7.6$ Hz, 3H). ^{13}C NMR (CDCl_3 , 100 MHz) δ : 148.3, 144.4, 134.8, 129.1, 128.7, 128.3, 128.0 (2), 125.7, 119.3, 54.2, 28.7, 15.5.




1-(2-methyl-5-nitrophenyl)-4-(4-propylphenyl)-1H-1,2,3-triazole (Table 1, entry 16): ^1H NMR (DMSO- d_6 , 400 MHz) δ : 9.07 (s, 1H), 8.42-8.35 (m, 2H), 7.88 (d, J = 8.0 Hz, 2H), 7.83 (d, J = 8.8 Hz, 1H), 7.32 (d, J = 8.0 Hz, 2H), 2.60 (t, J = 7.6 Hz, 2H), 2.40 (s, 3H), 1.68-1.58 (m, 2H), 0.92 (t, J = 7.6 Hz, 3H). ^{13}C NMR (DMSO- d_6 , 100 MHz) δ : 147.3, 146.5, 142.7, 141.6, 136.9, 133.3, 129.3, 128.0, 125.8, 124.5, 123.2, 121.2, 37.4, 24.4, 18.6, 14.0.




ethyl 2-(4-((4-nitrophenoxy)methyl)-1H-1,2,3-triazol-1-yl)acetate (Table 1, entry 17): ^1H NMR (CDCl_3 , 400 MHz) δ : 8.20 (dd, J = 7.6 Hz, 2.0 Hz, 2H), 7.84 (s, 1H), 7.08 (d, J = 8.0 Hz, 2H), 5.34 (s, 2H), 5.20 (s, 2H), 4.28 (q, J = 7.2 Hz, 2H), 1.31 (t, J = 7.2 Hz, 3H). ^{13}C NMR (CDCl_3 , 100 MHz) δ : 166.1, 163.1, 143.2, 141.9, 125.9, 124.5, 114.9, 62.6, 62.4, 51.0, 14.1.



1-benzyl-4-((4-nitrophenoxy)methyl)-1H-1,2,3-triazole (Table 1, entry 18): ^1H NMR (CDCl_3 , 400 MHz) δ : 8.15 (dd, J = 9.2 Hz, 1.2 Hz, 2H), 7.62 (s, 1H), 7.38-7.28 (m, 5H), 7.04 (d, J = 9.2 Hz, 2H), 5.55 (s, 2H), 5.26 (s, 2H). ^{13}C NMR (CDCl_3 , 100 MHz) δ : 163.2, 143.1, 141.8, 134.3, 129.2, 128.9, 128.2, 125.9, 123.2, 114.9, 62.4, 54.3.



1-(2-methyl-5-nitrophenyl)-4-((4-nitrophenoxy)methyl)-1H-1,2,3-triazole (Table 1, entry 19): ^1H NMR (DMSO- d_6 , 400 MHz) δ : 8.85 (s, 1H), 8.37 (d, J = 6.8 Hz, 2H), 8.26 (d, J = 8.8 Hz, 2H), 7.82 (d, J = 9.2 Hz, 1H), 7.34 (d, J = 9.2 Hz, 2H), 5.46 (s, 2H), 2.32 (s, 3H). 1.68-1.58 (m, 2H), 0.92 (t, J = 7.6 Hz, 3H). ^{13}C NMR (DMSO- d_6 , 100 MHz) δ : 163.6, 146.5, 142.7, 141.8, 141.5, 136.8, 133.3, 127.3, 126.3, 124.8, 121.5, 115.8, 62.2, 18.4.



3-(1-benzyl-1H-1,2,3-triazol-4-yl)aniline (Table 1, entry 20): ^1H NMR (CDCl_3 , 400 MHz) δ : 7.61 (s, 1H), 7.38-7.28 (m, 5H), 7.23 (s, 1H), 7.16 (t, J = 8.0 Hz, 1H), 7.09 (d, J = 7.6 Hz, 1H), 6.64 (d, J = 8.0 Hz, 1H), 5.55 (s, 2H), 3.35 (br s, 2H, NH_2). ^{13}C NMR (CDCl_3 , 100 MHz) δ : 148.3, 146.8, 134.7, 131.4, 129.7, 129.1, 128.8, 128.1, 119.6, 116.1, 115.0, 112.3, 54.2.

V. ^1H and ^{13}C NMR Spectra of the Products

